Havn Life Closes C$11.5 Million Bought Deal Financing

Biotech and pioneering psychedelic medicine company Havn Life recently closed a C$11.5 million bought deal public offering with Eight Capital. Here, the company sold 10,747,900 units at a price of $1.07 per unit for aggregate gross proceeds of $11,500,253. These figures include a fully exercised over allotment option on behalf of the underwriter. In other words, Eight Capital had the option to buy an additional 1,401,900 units when this deal was first announced, and they indeed seized the opportunity. Learn more about Eight Capital and other investment banks in psychedelic medicine here.

What does this tell us about Havn Life? First, their is a significant appetite amongst investors to invest in Havn Life right now. This should come as no surprise – readers will recall that Havn Life’s team is well positioned to thrive in this market. Experience holds a lot of weight in a nascent industry. Second, we’ll likely read more headlines pertaining to Havn Life’s financial success. This news is fantastic, but it is only a glimpse of what will likely be a wildly victorious year for Havn Life.

Curious to learn more about Havn Life? Check out our article regarding the company’s stance on corporate social responsibility, education, and public policy reform.

FULL PRESS RELEASE BELOW

Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing

VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP(the “Company” or “Havn Life”) is pleased to announce that, further to its news release dated December 15, 2020, the Company has completed its previously announced bought deal public offering of 10,747,900 units (the “Units“), including 1,401,900 Units issued pursuant to the Underwriter’s (as defined below) over-allotment option which was exercised in full, at a price of $1.07 per Unit (the “Offering Price“), for aggregate gross proceeds of $11,500,253 (the “Offering“). Eight Capital acted as underwriter in respect of the Offering (the “Underwriter“).

Each Unit consists of one common share in the capital of the Company (each, a “Share“) and one Share purchase warrant (each, a “Warrant“), with each Warrant entitling the holder thereof to purchase one additional Share at an exercise price of $1.34 for a period of 36 months from the date of issuance.

The securities offered have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or under any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereunder. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

On Behalf of The Board of Directors

Tim Moore
CEO

About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on FacebookTwitter and Instagram.

Contact:

Investor Relations: [email protected] 604 687 7130
Media: [email protected] 778 238 6096

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

SOURCE: Havn Life Sciences Inc.

Microdose Psychedelic Insights

Microdose Psychedelic Insights

Your Guide to the Business of Psychedelics. Our mission is to shift the world's perception of psychedelic medicine.